[Pulmonary infiltrates after initiation of treatment with infliximab for adult Still's disease].
Martín Carrasco
C
C
Hortal Reina
B
B
Fernández Vázquez
E
E
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010996:Pleural Effusion / Q000139:chemically induced; D001261:Pulmonary Atelectasis / Q000139:chemically induced; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008775:Methylprednisolone